Skip to main content

Table 2 Main baseline features in the eight patients meeting ASAS criteria [32] for peripheral spondyloarthritis

From: Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study

  Patient 14 Patient 15 Patient 16 Patient 17 Patient 18 Patient 19 Patient 20 Patient 21
Type of SpA AS AS AS AS uSpA uSpA PsA PsA
Sacroiliitis Grade 2 Grade 3 Grade 3 Grade 3 Grade 0 Grade 1 Grade 0 Grade 0
HLA-B27 + - + + + + - -
Gender Male Female Male Female Female Female Female Female
Disease duration (years) 8 15 19 6 10 10 10 20
Main articular and extraarticular symptoms Coxitis, arthritis Arthritis Arthritis, uveitis Peripheral enthesitis (Achilles tendon, knee, elbow), arthritis, chest pain Arthritis Arthritis, IBD, uveitis Arthritis, dactylitis, psoriasis, uveitis Arthritis, psoriasis
Concomitant NSAIDs/steroids (dosage) Yes/no No/yes (20 mg/day) Yes/yes (5 mg/day) Yes/yes (15 mg/day) Yes/yes (8 mg/day) No/yes (10 mg/day) Yes/yes (20 mg/day) Yes/yes (20 mg/day)
Concomitant DMARDs Methotrexate No Methotrexate Leflunomide Methotrexate Methotrexate Methotrexate Methotrexate
Previous biologics other than anti-TNF No Anakinra No Abatacept No No No No
  1. AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis [36]; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.